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Abstract
BACKGROUND—Care for infants born preterm or with major birth defects is costly. Specific 
estimates of financial burden for different payers are lacking, in part because use of administrative 
data to identify preterm infants and costs is challenging.
METHODS—We used private health insurance claims data and billing codes to identify live 
births during 2013 and calculated first-year expenditures for employer-sponsored health plans for 
infants born preterm, both overall and stratified by major birth defects.
RESULTS—We conservatively estimated that 7.7% of insured infants born preterm accounted for 
37% of $2.0 billion spent by participating plans on the care of infants born during 2013. With a 
mean difference in plan expenditures of ~$47 100 per infant, preterm births cost the included plans 
an extra $600 million during the first year of life. Extrapolating to the national level, we projected 
aggregate employer-sponsored plan expenditures of $6 billion for infants born preterm during 
2013. Infants with major birth defects accounted for 5.8% of preterm births but 24.5% of 
expenditures during infancy. By using an alternative algorithm to identify preterm infants, it was 
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revealed that incremental expenditures were higher: $78 000 per preterm infant and $14 billion 
nationally.
CONCLUSION—Preterm births (especially in conjunction with major birth defects) represent a 
substantial burden on payers, and efforts to mitigate this burden are needed. In addition, 
researchers need to conduct studies using linked vital records, birth defects surveillance, and 
administrative data to accurately and longitudinally assess per-infant costs attributable to preterm 
birth and the interaction of preterm birth with major birth defects.
Approximately 1 in 10 US infants are born preterm (<37 completed weeks’ gestation), 1 
with high costs of neonatal hospitalizations.2–4 Each year’s cohort of preterm births incurred 
an incremental lifetime societal cost of $26.2 billion in 2005 dollars, including $16.9 billion 
in health care costs.5 In addition, the medical costs of prematurity to employers6 and 
Medicaid have also been assessed.7 Estimates of the added cost of preterm birth to 
employer-sponsored health plans can be used to demonstrate to employers the financial 
benefit of preterm birth prevention.
Our objectives with this analysis were (1) to estimate the financial impact on US employer-
sponsored plans of medical care for infants born preterm during 2013 (both overall and 
among infants with and without major birth defects), and (2) review potential biases in 
estimates of per-infant incremental expenditures for preterm versus nonpreterm births from 
analyses in which stand-alone claims data are used to ascertain preterm birth and estimate 
health care expenditures. Because infants with birth defects are more likely to be born 
preterm5, 8 and have elevated use of health care, 9, 10 we excluded infants with 
malformations to provide a lower-bound estimate of the burden of preterm birth. Finally, 
although record linkage in studies in which researchers use vital records data are the gold 
standard for economic assessments of preterm birth, 5 administrative databases are often 
used to estimate health care costs, and it is important to understand their limitations.
METHODS
Data Source
We analyzed data from the Truven Health Analytics MarketScan Commercial Research 
Database, a nationwide sample of private health plans provided through employers with data 
for tens of millions of individuals with employer-sponsored insurance (ESI). We accessed 
MarketScan data via Treatment Pathways 4.0, an online analytic platform; our analysis was 
restricted to plans with prescription drug coverage, which include ~75% of all MarketScan 
enrollees. This platform does not enable linkages between infant and maternal records.
Inclusion Criteria
We used 2 distinct approaches to identify a cohort of newborn infants with a presumed birth 
hospitalization during the 2013 calendar year. One approach included all infants with both a 
diagnosis-related group (DRG) code of 789 to 795 in the principal diagnosis field for an 
inpatient admission and a diagnosis code of V30 to V39 to indicate a live birth associated 
with the same discharge; in addition, they had no claims or enrollment date before the first 
inpatient claim with a neonatal DRG. In the other approach, we excluded the 790 DRG code, 
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which refers to “extreme immaturity or respiratory distress syndrome, neonate.” The 
justification for that exclusion is that infants with respiratory distress syndrome (RDS) may 
be enrolled in a covered plan after diagnosis rather than at birth. In both approaches, we 
tracked services and expenditures for 12 months after the first claim.
Identifying Preterm Infants
To identify infants coded for preterm birth (gestational age <37 weeks), we used the 
presence of International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) codes 765.00 to 765.28 on the first neonatal hospital discharge. Those codes, 
together with others for term low birth weight (LBW) births, are used to bill for services 
relating to “disorders relating to short gestation and low birth weight” (Supplemental Table 
3). All other newborns were presumed to be nonpreterm. In previous studies, researchers 
indicated that the above ICD-9-CM codes are highly specific, with a positive predictive 
value of at least 90%.11, 12 However, the sensitivity is much lower (between 45% and 80%) 
and is particularly low for infants born at 35 or 36 weeks’ gestation.12, 13 Consequently, only 
a subset of infants born preterm are coded as preterm.
By using a list of ICD-9-CM codes for selected major birth defects (Supplemental Table 4), 
infants who had 1 or more inpatient claims with any of the selected codes or ≥2 claims in 
any setting at least 7 days apart were classified as having a major birth defect. Billing codes 
for major birth defects in a single claim have a low positive predictive value (typically 50% 
to 70%).11, 14, 15 We calculated incremental expenditures for preterm birth, both overall and 
excluding infants with major birth defects.
Outcomes and Sensitivity Analysis
We calculated net plan expenditures (reimbursements to providers by plans) during the first 
12 months of life, regardless of duration of enrollment. We reported all expenditures and 
expenditures associated with inpatient services. In addition, we reported total allowable 
charges after adjudication by the health plan, which consists of 2 parts: the plan payment and 
the expected out-of-pocket payment by beneficiaries.
As a sensitivity analysis, we restricted the primary analysis sample to infants with 
continuous enrollment for 12 months.
National Estimates
The aggregate additional expenditures by US employers on infancy care associated with 
preterm birth during 2013 were extrapolated from the study estimates by adjusting for the 
ratio of all births covered by ESI to the number of births in the data source. In 2013, private 
payers were responsible for 1 808 809 of 3 899 668 hospitalizations with a neonatal DRG 
code (789–795) (Health Care Utilization Project, Agency for Healthcare Research and 
Quality).16 In 2013, 93.4% of children aged <6 years with private health insurance had ESI 
coverage.17* Those estimates imply 1 746 901 neonatal admissions were covered nationally 
*In 2013 47.3% of children aged <6 years had private health insurance (Table 102) and 44.2% had employer-sponsored health 
insurance (Table 103).17
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by ESI during 2013. We used the ratio of this number to the number of neonatal admissions 
in our analytic sample to extrapolate employer-sponsored plan expenditures to the national 
level.
RESULTS
The number of infants with first neonatal hospitalizations during the 2 approaches in 2013 
were 180 787 (with the 790 DRG code) and 173 649 (excluding the 790 DRG code as an 
inclusion criterion). The number of insured infants with preterm billing codes were 17 795 
(9.8%) in the first approach and 13 426 (7.7%) in the second approach. Of the 7138 infants 
who had a 790 DRG code, virtually all (98%) also had an ICD-9-CM diagnosis code for 
RDS. The percentage of infants with an inpatient diagnosis of RDS was 4.4% of 180 787 
infants in the first approach by using the 790 DRG code to ascertain neonates and 0.9% of 
the 173 649 infants in the second approach. The latter estimate is consistent with population-
based neonatal RDS prevalence estimates of 1.2%.18, 19 Consequently, we treated the second 
approach as the primary analysis.
Per-Infant Expenditures
By using the second approach, mean net plan expenditures for infants classified as preterm 
were $54 873 compared with $7774 for nonpreterm infants, a mean difference of $47 099 
(Table 1).
Under the first approach, with an approximately fourfold higher RDS prevalence, mean net 
plan expenditures were $85 962 for preterm infants and $7942 for nonpreterm infants, a 
difference of $78 019 per infant (Table 1).
In a sensitivity analysis restricted to the 42% of infants with 12 months of continuous 
enrollment, per-child expenditures for the year were similar to those reported above (S.D.G., 
unpublished observations).
Mean inpatient expenditures accounted for 89% to 92% of overall net plan expenditures for 
preterm infants compared with 61% to 62% for nonpreterm infants (S.D.G., unpublished 
observations). Total mean allowable charges (ie, expected total payments to providers) per 
child were slightly higher than plan payments for infants coded as preterm (ie, expected out-
of-pocket payments) by $1883 to $2158 in absolute terms and 2.5% to 3.4% in relative 
terms; for other infants, total costs were higher by $961 to $1354, or 12.4% to 17.0% in 
relative terms (Table 1).
As is generally the case with health care expenditures, median expenditures (the payment for 
the average child) were considerably lower than mean expenditures (the average payment for 
all children in the group). The median was closer to the mean for the nonpreterm group than 
for the preterm birth group, which reflects a more skewed distribution of costs in the latter.
Aggregate Infant Spending and Attributable Preterm Birth Spending
The aggregate plan expenditures variable is the product of mean expenditures during the first 
12 months by the number of infants. For 173 649 infants in the second approach, aggregate 
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expenditures were ~$2.0 billion, of which ~$740 million (37.2%) were incurred by 7.7% of 
infants coded as preterm (Table 1). In the first approach, aggregate expenditures for the 
cohort of 180 787 infants were ~$2.9 billion, of which ~$1.5 billion (or 54.2% of total infant 
expenditures) were incurred by the 9.8% of infants classified as preterm.
The number of hospital deliveries in this study was ~10% of the 1 746 901 deliveries 
covered nationally by ESI during 2013.
Aggregate expenditures during infancy attributable to preterm births in the second approach 
were ~$632.4 million (the product of the incremental expenditure for preterm infants [$47 
099] and the number of infants coded as preterm [n = 13 426]). The national estimate of 
aggregate spending by employer-sponsored plans on medical care during infancy associated 
with preterm birth during 2013 was $6.3 billion in 2014 dollars in that approach. Aggregate 
preterm-attributable expenditures according to the first approach were ~$14 billion.
Per-Infant Expenditures Associated With Birth Defects
In the primary analysis (in which the second approach to identify newborns was used), 
infants with major birth defects comprised 6.5% of infants coded as preterm compared with 
2.3% of infants not coded as preterm. Mean expenditures for infants who did not meet the 
algorithm for confirmed major birth defects were 6.6 times higher for those born preterm: 
$42 620 vs $6450. The incremental expenditure associated with preterm birth among those 
without major birth defects was $36 171 (Table 2). The latter figure multiplied by the 
number of preterm infants without major birth defects (12 401) yields a lower-bound 
attributable expenditure for preterm birth among participating plans of $528.5 million, 
which is 16.5% lower than the primary estimate of $632.4 million. The mean expenditures 
for preterm infants with major birth defects ($226 840) is 3.5 times greater than for infants 
with major birth defects not coded as born preterm ($63 939). Preterm infants with major 
birth defects accounted for 27.5% of all expenditures for preterm infants.
DISCUSSION
In this study, we confirm previous findings that preterm birth is costly to US private health 
plans and employers.5, 6, 20 The estimates in this study relate to plan expenditures. Average 
payments by private health plans substantially exceed those of public payers, including 
Medicare and Medicaid.21 Estimates of average per-child Medicaid expenditures for preterm 
and/or LBW infants born during 2009 were only one-third as high as for infants in 
employer-sponsored plans.6, 7 Unlike the authors of a 2006 Institute of Medicine (IOM) 
report, 5 we did not include costs of pregnancy and delivery care or medical care after 
infancy, and therefore our medical cost estimates are partial. Furthermore, our estimates do 
not address societal costs, which include nonmedical services and lost economic production. 
Preterm birth is costly, and efforts to reduce its occurrence have large potential benefits.
We estimated an aggregate cost to US employer-sponsored plans of between $6 billion and 
$14 billion for infant care attributable to preterm birth during 2013. The difference between 
the 2 estimates reflects the differential inclusion of infants with a DRG code for RDS, 
representing 0.9% and 4.4% in the second and first approaches, respectively. Because the 
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former estimate is consistent with population-based neonatal RDS prevalence estimates of 
1.2%, 18, 19 we believe that it is closer to a representative cohort of privately insured 
newborns enrolled from birth. Conversely, the second cohort might have been enriched with 
infants with RDS. Consequently, we suspect that the aggregate economic impact of preterm 
birth on employer-sponsored health plans is likely to be much closer to the lower-bound 
estimate of $6 billion than the upper-bound estimate of $14 billion.
Our lower-bound estimate of $6 billion for the US employer insurance burden of preterm 
birth may appear low relative to a March of Dimes estimate of $12 billion in 2011 dollars.6 
However, that estimate included both maternity and infant care costs; infant care costs alone 
were just over $10 billion.6 It also included costs to families as well as costs to employer 
plans, although out-of-pocket expenditures by enrollees raised incremental expenditures in 
the current study by just 2%. Additionally, the comparison group was restricted to “healthy” 
term infants, whose mean expenditure in 2013 and 2014 dollars22 was 39% lower than the 
average expenditure for nonpreterm infants in the current study. Finally, the March of Dimes 
estimate included both LBW and preterm infants.6 Conversely, we directly estimated 
numbers of privately-insured infants who were coded as preterm rather than using estimates 
of preterm births indirectly derived from vital records. Aggregate cost estimates calculated 
by using the same ascertainment methods both to identify affected persons and to estimate 
per-person costs are preferred.23
Also, for the first time, we have quantified the overlap of medical costs during infancy for 
major birth defects and preterm birth. A recent analysis found that excluding hospital codes 
for preterm birth would reduce US birth defect–related hospital cost estimates by 
approximately one-fifth.10 More than one-quarter (27.5%) of total expenditures for infants 
born preterm were incurred by the 6.5% of preterm infants with major birth defects. It also 
appears that the cost of shorter gestation is higher for infants with major birth defects. In 
Australia, each additional completed week of gestation was found to reduce mean cost 
during the first year of life by 10% and 27% for infants with and without severe neonatal 
morbidity, respectively.24 Prevention of the synergistic combination of birth defects and 
preterm birth may yield higher cost savings.
Our estimates have limitations. First, MarketScan Commercial data are a convenience 
sample of the US population with ESI that over-represents states in the South and 
underrepresents states in the West, which have the highest expenditures.25 The average 
expenditures for preterm infants in the South were 12% less than the sample mean, and in 
the West they were 32% greater than the sample mean. Therefore, the unweighted 
expenditures likely underestimate expenditures for US ESI plans.
The most serious study limitation is the inability to reliably ascertain preterm birth in 
administrative databases. The ICD-9-CM diagnosis codes used to identify infants born 
preterm were developed to code diseases for purposes of reimbursement, not for surveillance 
of risk factors such as preterm birth. In particular, infants who are born at 35 to 36 weeks’ 
gestation and do not require additional hospital care are less likely to be coded as preterm 
and also have much lower hospital days than infants who are coded as preterm, similar to 
those born at term. Among infants who are relatively healthy, the association of preterm 
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birth with increased expenditures is lower than it is among those with severe neonatal 
morbidity.24 The implication is that the estimates of per-child expenditures associated with 
preterm birth (especially late preterm birth) may be substantially overstated by using stand-
alone administrative databases. On the other hand, the incomplete sensitivity of the ICD-9-
CM codes for ascertaining preterm births does not bias aggregate estimates of expenditures; 
rather, the aggregate estimates are conservative because they do not include any incremental 
health care cost for late preterm infants who are not coded as preterm.
Overstatement of expenditures for late preterm infants identified by using billing codes with 
stand-alone administrative databases relative to actual expenditures for all late preterm 
infants is illustrated by a comparison of published estimates from 2004 to 2005 MarketScan 
Commercial claims data26 and linked California vital records and hospital discharge data 
from 1998 to 2000.2 According to the MarketScan analysis, late preterm infants (33–36 
weeks’ gestation) had 12.6 times higher mean expenditures for the birth hospitalization than 
term infants.26 In the California analysis, the mean cost of birth hospitalizations when 
pooling gestational ages 33 to 36 weeks was 3.3 times higher than for infants with a 
gestational age of 37 weeks.2 The latter analysis, which used reliable estimates of gestational 
age in combination with linked administrative data, yields credible estimates of 
hospitalization costs by gestational age.
Not surprisingly, the average per-child expenditures reported in this study by using stand-
alone claims data are higher than the per-child cost estimates reported by the IOM 
committee on the basis of an analysis of linked birth certificate and administrative health 
care data.5 The average medical cost for all preterm infants during the birth year in the IOM 
study was $29 041 in 2005 dollars, 5 which, adjusted for 2013 and 2014 medical prices, 22 is 
equivalent to $35 527. Applying the gestational age composition of 2013 births1 to the 
stratified cost estimates in the IOM report5 yields a birth year cost estimate for 2013 births 
of $37 868. Part of the difference between this latter figure and the lower-bound estimate of 
$47 099 per infant in the current study is due to the difference between expenditures by 
employer-sponsored plans and population-level costs. An even more important contribution, 
however, is the lower likelihood that preterm infants without complications are coded as 
preterm. Consequently, the average expenditure for all infants born preterm is presumably 
lower than the estimates reported here.
The limitations of administrative health care databases can be remedied through the use of 
record linkages with nonadministrative databases (including vital records and birth defects 
surveillance systems) to validate diagnoses.27 Accurate estimates of per-child costs 
associated with preterm birth based on record linkage of administrative data with US vital 
records have been published.2, 5 A linkage of databases in New South Wales, Australia, has 
also generated estimates of the impact of preterm birth on health care costs during infancy 
and the first 6 years of life.24, 28 Similarly, linked databases have been used to assess health 
care use and costs for infants and young children with birth defects.9
Updated estimates of the preventable cost of prematurity could be used to project cost 
savings to health care payers and society from interventions that reduce the number of 
infants born preterm. Such estimates ideally should be specific to the outcomes of 
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interventions. For example, suppose it were possible to delay threatened preterm labor by 1 
week. How much would health care payers save for each infant whose gestational age was 
raised from 36 to 37 weeks? To answer that question, analyses of cost differences by single 
weeks of gestational age based on reliable obstetric estimates1 are needed.2 The present 
findings, which are limited to administrative data and billing codes, are too crude to be used 
for that purpose.
CONCLUSIONS
In the current study, we make 3 contributions. First, we provide conservative, lower-bound 
estimates of the financial impact of preterm birth on US employer-sponsored health plans. 
Second, we call attention to the synergistic interaction of preterm birth and major birth 
defects. Infants born with serious birth defects incur much higher costs if they are also born 
preterm. Third, we identify inherent limitations with the use of standalone administrative 
databases for research on prematurity and suggest an alternative research approach based on 
the exploitation of record linkages of administrative health care data with data containing 
validated estimates of gestational age.
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What’s Known on This Subject
Preterm infants often incur high medical costs. Lifetime medical costs for US infants 
born preterm in 2005 were $17 billion higher than for other infants. Birth defects were 
associated with $9 billion in hospital costs during infancy in 2013.
What This Study Adds
Employer-sponsored health plans in the United States paid at least $6 billion extra for 
infants born preterm during 2013, one-quarter of which was associated with the 6% of 
preterm infants who had major birth defects.
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